Hematology and Immunology, Kanazawa Medical University, Uchinada, Japan.
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, USA.
Int J Hematol. 2022 Sep;116(3):393-400. doi: 10.1007/s12185-022-03368-y. Epub 2022 May 10.
We compared the outcomes of autologous stem cell transplantation (auto-SCT) with those of allogeneic stem cell transplantation (allo-SCT) from a human leukocyte antigen-matched related donor in patients with Philadelphia chromosome-negative B-lineage acute lymphoblastic leukemia (ALL). Newly diagnosed patients who underwent allo-SCT (n = 486) or auto-SCT (n = 99) after achieving first complete remission (CR) were included. Propensity score matching (PS) and an inverse probability of the treatment weighting (IPTW) analysis were applied to compensate for imbalances in baseline characteristics. The 5 years rates of overall survival (OS) among those in the PS-matched cohorts were 57% [95% confidence interval (CI) 46-67%] for those who received allo-SCT and 44% (95% CI 33-54%) for those who received auto-SCT. Multivariable, propensity score-matched, and IPTW analyses all revealed no statistically significant differences in OS between the two groups [hazard ratios (HR) 0.81, 95% CI 0.53-1.27, p = 0.36; HR 0.84, 95% CI 0.40-1.78, p = 0.65; HR 0.71, 95% CI 0.25-2.02, p = 0.53, respectively]. Prospective trials that include autologous transplantation as a treatment option are needed to examine the potential of autologous transplantation.
我们比较了在费城染色体阴性 B 细胞急性淋巴细胞白血病(ALL)患者中,来自人类白细胞抗原匹配相关供体的自体干细胞移植(auto-SCT)与异基因干细胞移植(allo-SCT)的结果。纳入了首次完全缓解(CR)后接受 allo-SCT(n=486)或 auto-SCT(n=99)的新诊断患者。应用倾向评分匹配(PS)和治疗反概率加权(IPTW)分析来补偿基线特征的不平衡。PS 匹配队列中,allo-SCT 组和 auto-SCT 组的 5 年总生存率(OS)分别为 57%(95%CI 46-67%)和 44%(95%CI 33-54%)。多变量、倾向评分匹配和 IPTW 分析均显示两组间 OS 无统计学差异[风险比(HR)0.81,95%CI 0.53-1.27,p=0.36;HR 0.84,95%CI 0.40-1.78,p=0.65;HR 0.71,95%CI 0.25-2.02,p=0.53]。需要开展包含自体移植作为治疗选择的前瞻性试验,以检验自体移植的潜力。